Announcement on Subsidiary Companies Participating in the Fourth Batch of National Drug Centralized Procurement to be Bwon
Release time:
2021-05-20
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Lin 2021-003
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Subsidiaries Participating in the Fourth Batch of National Centralized Drug Procurement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
On February 3, 2021 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Group" or "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), participated in the fourth batch of national centralized drug procurement bids organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"), peak Pharmaceutical's Olopatadine Hydrochloride Eye Drops is proposed to win the bid for this centralized procurement. The relevant information is hereby announced as follows:
Basic Situation of 1. Proposed Winning Products
Proposed Winning Products |
Specifications |
Indications |
Proposed Winning Price |
Proposed Winning Quantity |
Provinces |
Olopatadine Hydrochloride Eye Drops |
5ml:5mg (0.1%) |
is suitable for treating signs and symptoms of allergic conjunctivitis |
19.9 yuan/ box |
36.23 box |
Shanghai, Zhejiang, Guangdong, Sichuan, Henan, Liaoning, Hubei, Chongqing, Hunan, Shaanxi, Anhui, Hainan, Xinjiang (including bingtuan), Jiangxi, Qinghai, Tibet |
the bid price and the bid quantity of the above varieties are subject to the final data released by the joint procurement office. According to the relevant winning rules, the bid period for this bid is 1 year.
The impact of 2.'s proposed winning the bid on the company
Jianfeng Pharmaceutical's proposed winning product Olopatadine Hydrochloride Eye Drops obtained the approval of State Drug Administration and issued Drug Registration Approval Document in 4 in 2019 . The market sales volume of was relatively small before , the sales revenue of this product in 2019 and 2020 1-9 September are 5.65 .01 million yuan and 97.74 .03 million yuan respectively, accounting for 2019 annual operating revenue 354 respectively, 753.76 .07 million yuan of 0.0016% and 2020 1-9 March operating income 224,065.44 .15 million yuan of 0.04% .
This centralized procurement is the fourth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to the drugs selected in this centralized drug procurement and ensure the completion of the agreed procurement volume. The price of the products to be selected this time has decreased to a certain extent compared with the original price. If the company subsequently signs a purchase contract and implements it, it will help expand the sales scale of the product, increase market share, and enhance the company's brand influence, which has a positive impact.3. Risk Alert
At present, the company has signed the "Memorandum of National Drug Centralized Procurement of Selected Varieties" with the Joint Procurement Office. There is still uncertainty about the follow-up matters such as the signing of the purchase agreement for the above products and the impact on the company's future performance. The company will pay close attention to the progress of the matter and timely discharge of information disclosure obligations, so that the majority of investors cautious decision-making, pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
February 5, 2001
More information
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-22
Company fully deploys 2019 work
On January 28, the group company held a business analysis meeting to review and summarize the work situation in 2018, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises made reports on the overall work situation in 2018, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2019. Xiang Chongping, deputy general manager of the group company, made a systematic review of the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the internal control, safety and environmental protection work in 2018. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2018 and made a comparative analysis of the main economic indicators of each industrial sector. In 2018, the operating indicators of the company's various industrial sectors have improved significantly year-on-year, and the group company has also created the best operating performance in history. All units have completed the formulation of the second round of "three-year business plan", which points out the direction for the next three years of business work; the group company has also completed the first draft of the new "five-year strategic development plan", which is being revised and enriched. In addition, the two main businesses have also made substantial progress in investment expansion and industrial integration around strategic objectives, and the operating costs of major enterprises have decreased to varying degrees; the optimization of organizational structure and post setting has achieved new results, and management efficiency and people
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-30
The truth about private equity investments you need to know.
China Securities Regulatory Commission Zhejiang Regulatory Bureau and China Securities Investor Protection Fund Co., Ltd. jointly launched the "those private equity fund investment truth you need to know" investment education products. With the outbreak of private equity investment, the proportion of individual investors has further increased, and there are more and more "rich myth" scams. But the things behind "private placement" may not be as simple as you think, and risk prevention knowledge needs to be known early.
2020
07-31
Chairman Jiang Xiaomeng Directs Work in Yunnan Peak
On December 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, went to Yunnan Jianfeng cement company to investigate and guide the work. On the morning of the same day, accompanied by the Yunnan peak management team, Jiang Xiaomeng went deep into the front line and successively went to the central control room of the production and manufacturing department, the raw material clay yard, the lignite yard and other areas for field investigation and investigation to understand the problems existing in the production and operation process. Subsequently, a business analysis meeting was held to make a comparative analysis of the various business indicators of Yunnan Jianfeng from January to November this year, and put forward two requirements to the management team: further strengthen internal management and improve execution; strengthen the coordination of external relations, and improve The ability and level of enterprise resource acquisition. At the Yunnan Jianfeng middle-level cadre meeting held on the afternoon of the 16th, Jiang Xiaomeng first fully affirmed Yunnan Jianfeng's highest output and best benefits since it was put into production in 2018, and expressed his gratitude to all cadres and employees of Yunnan Jianfeng for their hard work. After that, Jiang Xiaomeng made a detailed analysis of the cement industry and the regional market environment in Yunnan, and combined with the current production and operation situation of Yunnan Jianfeng, put forward the focus of the next step: 1. should fully attach importance to and mobilize the initiative and responsibility of employees at all levels to improve the overall execution of the team; 2. raw material mines are an important factor restricting the future development of cement enterprises, which should be paid full attention to and formulate clear strategies and methods, set out a timetable to obtain future production resources as much as possible; 3. continuously advocate and promote technological innovation, keep pace with the times, continuously improve production management, equipment management, production technology level, and maintain the competitive advantage of the industry; 4. further strengthen production
2020
07-31